TREATMENT OF ADVANCED BREAST-CANCER WITH AMINOGLUTETHIMIDE - RESPONSE AFTER PREVIOUS TAMOXIFEN TREATMENT
- 1 January 1984
- journal article
- research article
- Vol. 66 (10) , 372-374
Abstract
Postmenopausal patients (31) with advanced breast cancer either unresponsive to tamoxifen or progressing after responding to tamoxifen were treated with aminoglutethimide (1000-1250 mg/day) plus hydrocortisone replacement. The response rate was 33% in patients who had never responded to tamoxifen and 47% in patients who had previously responded to tamoxifen. The overall response rate was 42%. These results show that aminoglutethimide is an effective 2nd-line hormonal treatment for patients with advanced breast cancer.This publication has 7 references indexed in Scilit:
- Endocrine effects of low dose aminoglutethimide alone in advanced postmenopausal breast cancerBritish Journal of Cancer, 1983
- Treatment of metastatic breast cancer in estrogen receptor positive patients a randomized trial comparing tamoxifen alone versus tamoxifen plus CMFCancer, 1982
- Treatment of advanced breast cancer with aminoglutethimide after therapy with tamoxifenCancer, 1982
- A Randomized Trial Comparing Surgical Adrenalectomy with Aminoglutethimide plus Hydrocortisone in Women with Advanced Breast CancerNew England Journal of Medicine, 1981
- Comparison of tamoxifen and hypophysectomy in breast cancer treatmentCancer, 1980
- Assessment of response to therapy in advanced breast cancer.A project of the programme on clinical oncology of the International Union against Cancer, Geneva, SwitzerlandCancer, 1977
- Inhibition of Adrenal Corticosteroid Synthesis by Aminoglutethimide: Studies of the Mechanism of Action1Journal of Clinical Endocrinology & Metabolism, 1967